TrialBMJ (Clinical research ed.)2026

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Zhi Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.